COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04154709
Recruitment Status : Recruiting
First Posted : November 6, 2019
Last Update Posted : January 14, 2020
Nanjing Bioheng Biotech Co., Ltd.
Information provided by (Responsible Party):
Kai Lin Xu; Jun Nian Zheng, Xuzhou Medical University

Brief Summary:
This study aims to evaluate the safety and feasibility of CTA101 in treating patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia Biological: CTA101 Phase 1

Detailed Description:
This study is indicated for r/r CD19+ B-ALL, the selection of dose levels and the number of subjects are based on clinical trial of similar foreign product, whose primary objective was to explore the safety, main consideration was dose-related safety.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia
Actual Study Start Date : December 10, 2019
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : June 2022

Arm Intervention/treatment
Experimental: CTA101
Dose escalation follows the accelerated titration and the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
Biological: CTA101
Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.

Primary Outcome Measures :
  1. Dose-limiting toxicity(DLT) [ Time Frame: Baseline up to 28 days after T cell infusion ]
    Adverse events assessed according to NCI-CTCAE v5.0 criteria

Secondary Outcome Measures :
  1. MRD negative overall response rate (MRD- ORR) [ Time Frame: 3 months ]
    Assessment of MRD negative overall response rate (MRD- ORR) at 3 months of treatment

  2. Overall response rate (ORR) [ Time Frame: Month 6, 12, 18 and 24 ]
    Assessment of ORR (ORR = CR + CRi ) at Month 6, 12, 18 and 24

  3. Event-free survival (EFS) [ Time Frame: Month 6, 12, 18 and 24 ]
    Assessment of EFS at Month 6, 12, 18 and 24

  4. Overall survival (OS) [ Time Frame: Month 6, 12, 18 and 24 ]
    Assessment of OS at Month 6, 12, 18 and 24

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female aged 3-70 years old;
  2. Histologically confirmed diagnosis of CD19+ B-ALL per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphoblastic Leukemia (2016.v1);
  3. Relapsed or refractory CD19+ B-ALL (meeting one of the following conditions):

    1. CR not achieved after standardized chemotherapy;
    2. CR achieved following the first induction, but CR duration is ≤ 12 months;
    3. Ineffectively after first or multiple remedial treatments;
    4. 2 or more recurrences;
  4. The number of primordial cells (lymphoblast and prolymphocyte) in bone marrow is﹥5%;
  5. Philadelphia-chromosome-negative (Ph-) patients; or Philadelphia-chromosome-positive (Ph+) patients who cannot tolerate TKI treatments or do not respond to 2 TKI treatments;
  6. Serum albumin ≥ 30g/L, total bilirubin ≤ 25.7umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8umol/L, platelet count ≥ 50*10^9/L;
  7. Echocardiogram (ECHO) shows left ventricular ejection fraction (LVEF) ≥ 50%;
  8. No active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%;
  9. Latest treatment (radiotherapy, chemotherapy, monoclonal antibody therapy or other treatment) must have been completed at least 2 weeks prior to screening;
  10. Estimated survival time ≥ 3 months;
  11. ECOG performance status 0 to 1;
  12. Patients or their legal guardians volunteer to participate in the study and sign the informed consent.

Exclusion Criteria:

  1. History of hypersensitivity to any component of cell product;
  2. Prior treatment with any CAR T cell product or other genetically-modified T cell therapies;
  3. Patients with extramedullary lesions;
  4. Confirmed diagnosis of lymphoblastic crisis of chronic myeloid leukemia, Burkitt's leukemia/ lymphoma per WHO Classification Criteria;
  5. Patients with hereditary syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome;
  6. Patients with New York Heart Associate (NYHA) Class III/IV cardiac insufficiency;
  7. Myocardial infarction, cardioangioplasty or stenting, unstable angina pectoris, or other severe cardiac diseases within 12 months of enrollment;
  8. Severe primary or secondary hypertension of grade 3 or above (WHO Hypertension Guidelines, 1999);
  9. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases;
  10. Central nervous system leukemia (CNS2 or CNS3), resistant to intrathecal injecting of chemotherapeutic drugs, and/or undergoing skull and/or spine radiotherapy; patients with history of CNS but effectively controlled to allow enrollment;
  11. Prior treatment with TKIs (Ph+ ALL) 1 week prior to enrollment;
  12. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis), or currently receiving antibiotic therapy by intravenous infusion, or have received antibiotic treatment by intravenous infusion within 1 week before cell infusion. However, prophylactic antibiotic, antiviral and antifungal treatments are allowed;
  13. Indwelling catheters in vivo (e.g. percutaneous nephrostomy, Foley catheter, bile duct catheter, or pleural/peritoneal/pericardial catheter). Ommaya storage, dedicated central venous access catheters such as Port-a-Cath or Hickman catheters are allowed;
  14. History of other primary cancer, except for the following conditions:

    1. Cured non-melanoma after resection, such as basal cell carcinoma of the skin;
    2. Cervical cancer in situ, localized prostate cancer, ductal cancer in situ with disease-free survival ≥ 2 years after adequate treatment;
  15. Patients with autoimmune diseases requiring treatment, patients with immunodeficiency or requiring immunosuppressive therapy;
  16. Patients with graft-versus-host disease (GVHD);
  17. If HBsAg positive at screening, HBV DNA copy number detected by PCR in patients with active hepatitis B > 1000 (if HBV DNA copy number≤1000, routine antiviral therapy is required after enrollment), as well as CMV, hepatitis C, syphilis and HIV infection;
  18. Concurrent therapy with systemic steroids within 1 week prior to screening, except for the patients recently or currently receiving inhaled steroids;
  19. Women pregnant or lactating, with a pregnancy plan within 6 months, fertile but unable to take medically acceptable contraception measures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04154709

Layout table for location contacts
Contact: Li Zhenyu, Ph.D 15950688971

Layout table for location information
China, Jiangsu
Affiliated hospital of Xuzhou medical college Recruiting
Xuzhou, Jiangsu, China, 221000
Contact: Jiang Cao, M.D., Ph.D.    86-516-85802291   
Sponsors and Collaborators
Kai Lin Xu; Jun Nian Zheng
Nanjing Bioheng Biotech Co., Ltd.
Layout table for additonal information
Responsible Party: Kai Lin Xu; Jun Nian Zheng, President, Xuzhou Medical University Identifier: NCT04154709    
Other Study ID Numbers: XYFY2019-KL135-02
First Posted: November 6, 2019    Key Record Dates
Last Update Posted: January 14, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases